<DOC>
	<DOCNO>NCT02810223</DOCNO>
	<brief_summary>This single arm , open-label , multi-center study determine efficacy safety experimental therapy call CART-19 patient chemo-refractory relapsed B-cell ALL .</brief_summary>
	<brief_title>Efficacy CART-19 Cell Therapy B Cell Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>This single arm , open-label , multi-center , phase I study determine efficacy CTL019 patient r/r B-cell ALL . The study follow sequential phase : Screening , Pre-Treatment ( Cell Product Preparation &amp; Lymphodepleting Chemotherapy ) , Treatment Primary Follow-up , Secondary Follow-up ( applicable ) Survival Follow-up .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>Male female subject CD 19+ B cell acute lymphoblastic leukemia patient available curative treatment option ( autologous allogeneic SCT ) limit prognosis ( several month &lt; 2 year survival ) currently available therapy enrol 1 . Age 1 60 year . 2 . Expected survival &gt; 12 week 3 . Creatinine &lt; 2.5 mg/dl less 2.5x normal age 4 . ALT ≤ 5x normal 5 . Bilirubin &lt; 2.0 mg/dl 6 . Any relapse prior SCT make patient eligible regardless prior therapy 7 . Patients relapse disease prior allogeneic SCT ( myeloablative nonmyeloablative ) eligible meet inclusion criterion ① . Have active GVHD require immunosuppression ② . Are 4 month transplant 8 . For patient require leukapheresis T cell collection ( i.e . previously collect product exists ) , adequate venous access apheresis eligible appropriate catheter placement , contraindication leukapheresis 9 . Voluntary inform consent give 10 . Patients CNS3 disease eligible CNS disease responsive therapy ( infusion ) 1 . Pregnant lactating woman . The safety therapy unborn child know . Female study participant reproductive potential must negative serum urine pregnancy test perform within 48 hour infusion 2 . Uncontrolled active infection 3 . Active hepatitis B hepatitis C infection 4 . Concurrent use systemic steroid time cell infusion cell collection , condition , treat physician 's opinion , likely require steroid therapy collection infusion . Steroids disease treatment time cell collection time infusion permit . Use inhaled steroid , hydrocortisone physiological replacement patient adrenal insufficiency permit well 5 . Presence grade 24 acute extensive chronic GVHD 6 . Under treatment GVHD 7 . Previous treatment gene therapy product 8 . Any uncontrolled active medical disorder would preclude participation outline . 9 . HIV infection . 10 . CNS3 disease progressive therapy , CNS parenchymal lesion might increase risk CNS toxicity</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>